Multicenter case series of standalone XEN implant vs. combination with phacoemulsification in Turkish patients
Purpose To evaluate and compare the efficacy, safety and needling timing and rates of standalone XEN implant vs. combination with phacoemulsification in Turkish patients. Methods Retrospective, multicenter study which included the data of patients, who had open angle glaucoma including primary open...
Gespeichert in:
| Veröffentlicht in: | International ophthalmology 2021-10, Vol.41 (10), p.3371-3379 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3379 |
|---|---|
| container_issue | 10 |
| container_start_page | 3371 |
| container_title | International ophthalmology |
| container_volume | 41 |
| creator | Eraslan, Muhsin Özcan, Altan Atakan Dericioğlu, Volkan Çiloğlu, Emine |
| description | Purpose
To evaluate and compare the efficacy, safety and needling timing and rates of standalone XEN implant vs. combination with phacoemulsification in Turkish patients.
Methods
Retrospective, multicenter study which included the data of patients, who had open angle glaucoma including primary open angle glaucoma and pseudoexfoliation glaucoma, underwent standalone XEN implantation (XEN alone) and combined surgery with phacoemulsification (XEN + Phaco) between 2016 and 2018.
Results
The study included 26 eyes of 24 patients in XEN alone group and 32 eyes of 30 patients in XEN + Phaco group. The mean intraocular pressure (IOP) was 23.3 ± 6.0 mmHg and 24.4 ± 7.4 mmHg at baseline (
p
= 0.838), and it reduced to 16.3 ± 3.0 mmHg and 16.4 ± 2.3 mmHg at 12-month follow-up (
p
= 0.436) in XEN alone and XEN + Phaco groups, respectively (reduction: %30 and %33, P = 0.642). The mean number of medications reduced from 2.9 + 0.7 before surgery to 0.9 + 0.9 on month 12. In XEN alone and XEN + Phaco groups, the needling rates were 42.3% and 31.2% (
p
= 0.491), and the mean time to needling was 3.7 ± 3.2 months and 4.9 ± 8.0 months (
p
= 0.696), respectively. Hypotonia (17.2%) and hyphema (10.3%) were the most frequent complications, respectively. In XEN alone and XEN + Phaco groups, partial success was achieved in 73.1% and 71.9% of eyes when defined as IOP |
| doi_str_mv | 10.1007/s10792-021-01899-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2534610460</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2534610460</sourcerecordid><originalsourceid>FETCH-LOGICAL-c352t-d95a3532153d8a320cac37b50a2cf7d08ca66a1f33ca22eccb4a930324ffe8b73</originalsourceid><addsrcrecordid>eNp9kU1LxDAQhoMouK7-AU8BL16qk6RptkdZ1g_w47KCt5DNphptkzXTKv57oxUED54G5n3mnRleQg4ZnDAAdYoMVM0L4KwANqvrQm2RCZNKFLwSsE0mwCpZSAVsl-whPgNArepqQsLN0PbeutC7RK1BR9El75DGhmJvwtq0MTj6sLilvtu0JvT0DU-ojd3KB9P7GOi775_o5snY6LqhRd94Owo-0OWQXjxmOXfyDtwnO41p0R381Cm5P18s55fF9d3F1fzsurBC8r5Y19IIKTiTYj0zgoM1VqiVBMNto9Yws6aqDGuEsIZzZ-2qNLUAwcumcbOVElNyPPpuUnwdHPa682hdmx9wcUDNpSgrBmUFGT36gz7HIYV8XaZUmSFVs0zxkbIpIibX6E3ynUkfmoH-ikCPEegcgf6OQH9dIcYhzHB4dOnX-p-pT0R_iu4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2574104791</pqid></control><display><type>article</type><title>Multicenter case series of standalone XEN implant vs. combination with phacoemulsification in Turkish patients</title><source>SpringerLink Journals - AutoHoldings</source><creator>Eraslan, Muhsin ; Özcan, Altan Atakan ; Dericioğlu, Volkan ; Çiloğlu, Emine</creator><creatorcontrib>Eraslan, Muhsin ; Özcan, Altan Atakan ; Dericioğlu, Volkan ; Çiloğlu, Emine</creatorcontrib><description>Purpose
To evaluate and compare the efficacy, safety and needling timing and rates of standalone XEN implant vs. combination with phacoemulsification in Turkish patients.
Methods
Retrospective, multicenter study which included the data of patients, who had open angle glaucoma including primary open angle glaucoma and pseudoexfoliation glaucoma, underwent standalone XEN implantation (XEN alone) and combined surgery with phacoemulsification (XEN + Phaco) between 2016 and 2018.
Results
The study included 26 eyes of 24 patients in XEN alone group and 32 eyes of 30 patients in XEN + Phaco group. The mean intraocular pressure (IOP) was 23.3 ± 6.0 mmHg and 24.4 ± 7.4 mmHg at baseline (
p
= 0.838), and it reduced to 16.3 ± 3.0 mmHg and 16.4 ± 2.3 mmHg at 12-month follow-up (
p
= 0.436) in XEN alone and XEN + Phaco groups, respectively (reduction: %30 and %33, P = 0.642). The mean number of medications reduced from 2.9 + 0.7 before surgery to 0.9 + 0.9 on month 12. In XEN alone and XEN + Phaco groups, the needling rates were 42.3% and 31.2% (
p
= 0.491), and the mean time to needling was 3.7 ± 3.2 months and 4.9 ± 8.0 months (
p
= 0.696), respectively. Hypotonia (17.2%) and hyphema (10.3%) were the most frequent complications, respectively. In XEN alone and XEN + Phaco groups, partial success was achieved in 73.1% and 71.9% of eyes when defined as IOP < 18 mmHg with any medication, respectively (
p
= 0.920).
Conclusion
The XEN implant provides significant reduction in IOP and number of medications, either standalone or combination with phacoemulsification. Both procedures need intensive postoperative care, requiring needling in approximately one-third of patients.</description><identifier>ISSN: 0165-5701</identifier><identifier>EISSN: 1573-2630</identifier><identifier>DOI: 10.1007/s10792-021-01899-7</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Complications ; Eye ; Glaucoma ; Hypotonia ; Intraocular pressure ; Medicine ; Medicine & Public Health ; Ophthalmology ; Original Paper ; Patients ; Surgery</subject><ispartof>International ophthalmology, 2021-10, Vol.41 (10), p.3371-3379</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2021</rights><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c352t-d95a3532153d8a320cac37b50a2cf7d08ca66a1f33ca22eccb4a930324ffe8b73</citedby><cites>FETCH-LOGICAL-c352t-d95a3532153d8a320cac37b50a2cf7d08ca66a1f33ca22eccb4a930324ffe8b73</cites><orcidid>0000-0002-1829-3329 ; 0000-0002-1266-3333 ; 0000-0002-5563-8234 ; 0000-0001-6264-5304</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10792-021-01899-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10792-021-01899-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Eraslan, Muhsin</creatorcontrib><creatorcontrib>Özcan, Altan Atakan</creatorcontrib><creatorcontrib>Dericioğlu, Volkan</creatorcontrib><creatorcontrib>Çiloğlu, Emine</creatorcontrib><title>Multicenter case series of standalone XEN implant vs. combination with phacoemulsification in Turkish patients</title><title>International ophthalmology</title><addtitle>Int Ophthalmol</addtitle><description>Purpose
To evaluate and compare the efficacy, safety and needling timing and rates of standalone XEN implant vs. combination with phacoemulsification in Turkish patients.
Methods
Retrospective, multicenter study which included the data of patients, who had open angle glaucoma including primary open angle glaucoma and pseudoexfoliation glaucoma, underwent standalone XEN implantation (XEN alone) and combined surgery with phacoemulsification (XEN + Phaco) between 2016 and 2018.
Results
The study included 26 eyes of 24 patients in XEN alone group and 32 eyes of 30 patients in XEN + Phaco group. The mean intraocular pressure (IOP) was 23.3 ± 6.0 mmHg and 24.4 ± 7.4 mmHg at baseline (
p
= 0.838), and it reduced to 16.3 ± 3.0 mmHg and 16.4 ± 2.3 mmHg at 12-month follow-up (
p
= 0.436) in XEN alone and XEN + Phaco groups, respectively (reduction: %30 and %33, P = 0.642). The mean number of medications reduced from 2.9 + 0.7 before surgery to 0.9 + 0.9 on month 12. In XEN alone and XEN + Phaco groups, the needling rates were 42.3% and 31.2% (
p
= 0.491), and the mean time to needling was 3.7 ± 3.2 months and 4.9 ± 8.0 months (
p
= 0.696), respectively. Hypotonia (17.2%) and hyphema (10.3%) were the most frequent complications, respectively. In XEN alone and XEN + Phaco groups, partial success was achieved in 73.1% and 71.9% of eyes when defined as IOP < 18 mmHg with any medication, respectively (
p
= 0.920).
Conclusion
The XEN implant provides significant reduction in IOP and number of medications, either standalone or combination with phacoemulsification. Both procedures need intensive postoperative care, requiring needling in approximately one-third of patients.</description><subject>Complications</subject><subject>Eye</subject><subject>Glaucoma</subject><subject>Hypotonia</subject><subject>Intraocular pressure</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmology</subject><subject>Original Paper</subject><subject>Patients</subject><subject>Surgery</subject><issn>0165-5701</issn><issn>1573-2630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU1LxDAQhoMouK7-AU8BL16qk6RptkdZ1g_w47KCt5DNphptkzXTKv57oxUED54G5n3mnRleQg4ZnDAAdYoMVM0L4KwANqvrQm2RCZNKFLwSsE0mwCpZSAVsl-whPgNArepqQsLN0PbeutC7RK1BR9El75DGhmJvwtq0MTj6sLilvtu0JvT0DU-ojd3KB9P7GOi775_o5snY6LqhRd94Owo-0OWQXjxmOXfyDtwnO41p0R381Cm5P18s55fF9d3F1fzsurBC8r5Y19IIKTiTYj0zgoM1VqiVBMNto9Yws6aqDGuEsIZzZ-2qNLUAwcumcbOVElNyPPpuUnwdHPa682hdmx9wcUDNpSgrBmUFGT36gz7HIYV8XaZUmSFVs0zxkbIpIibX6E3ynUkfmoH-ikCPEegcgf6OQH9dIcYhzHB4dOnX-p-pT0R_iu4</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Eraslan, Muhsin</creator><creator>Özcan, Altan Atakan</creator><creator>Dericioğlu, Volkan</creator><creator>Çiloğlu, Emine</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1829-3329</orcidid><orcidid>https://orcid.org/0000-0002-1266-3333</orcidid><orcidid>https://orcid.org/0000-0002-5563-8234</orcidid><orcidid>https://orcid.org/0000-0001-6264-5304</orcidid></search><sort><creationdate>20211001</creationdate><title>Multicenter case series of standalone XEN implant vs. combination with phacoemulsification in Turkish patients</title><author>Eraslan, Muhsin ; Özcan, Altan Atakan ; Dericioğlu, Volkan ; Çiloğlu, Emine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c352t-d95a3532153d8a320cac37b50a2cf7d08ca66a1f33ca22eccb4a930324ffe8b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Complications</topic><topic>Eye</topic><topic>Glaucoma</topic><topic>Hypotonia</topic><topic>Intraocular pressure</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmology</topic><topic>Original Paper</topic><topic>Patients</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eraslan, Muhsin</creatorcontrib><creatorcontrib>Özcan, Altan Atakan</creatorcontrib><creatorcontrib>Dericioğlu, Volkan</creatorcontrib><creatorcontrib>Çiloğlu, Emine</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eraslan, Muhsin</au><au>Özcan, Altan Atakan</au><au>Dericioğlu, Volkan</au><au>Çiloğlu, Emine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicenter case series of standalone XEN implant vs. combination with phacoemulsification in Turkish patients</atitle><jtitle>International ophthalmology</jtitle><stitle>Int Ophthalmol</stitle><date>2021-10-01</date><risdate>2021</risdate><volume>41</volume><issue>10</issue><spage>3371</spage><epage>3379</epage><pages>3371-3379</pages><issn>0165-5701</issn><eissn>1573-2630</eissn><abstract>Purpose
To evaluate and compare the efficacy, safety and needling timing and rates of standalone XEN implant vs. combination with phacoemulsification in Turkish patients.
Methods
Retrospective, multicenter study which included the data of patients, who had open angle glaucoma including primary open angle glaucoma and pseudoexfoliation glaucoma, underwent standalone XEN implantation (XEN alone) and combined surgery with phacoemulsification (XEN + Phaco) between 2016 and 2018.
Results
The study included 26 eyes of 24 patients in XEN alone group and 32 eyes of 30 patients in XEN + Phaco group. The mean intraocular pressure (IOP) was 23.3 ± 6.0 mmHg and 24.4 ± 7.4 mmHg at baseline (
p
= 0.838), and it reduced to 16.3 ± 3.0 mmHg and 16.4 ± 2.3 mmHg at 12-month follow-up (
p
= 0.436) in XEN alone and XEN + Phaco groups, respectively (reduction: %30 and %33, P = 0.642). The mean number of medications reduced from 2.9 + 0.7 before surgery to 0.9 + 0.9 on month 12. In XEN alone and XEN + Phaco groups, the needling rates were 42.3% and 31.2% (
p
= 0.491), and the mean time to needling was 3.7 ± 3.2 months and 4.9 ± 8.0 months (
p
= 0.696), respectively. Hypotonia (17.2%) and hyphema (10.3%) were the most frequent complications, respectively. In XEN alone and XEN + Phaco groups, partial success was achieved in 73.1% and 71.9% of eyes when defined as IOP < 18 mmHg with any medication, respectively (
p
= 0.920).
Conclusion
The XEN implant provides significant reduction in IOP and number of medications, either standalone or combination with phacoemulsification. Both procedures need intensive postoperative care, requiring needling in approximately one-third of patients.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><doi>10.1007/s10792-021-01899-7</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-1829-3329</orcidid><orcidid>https://orcid.org/0000-0002-1266-3333</orcidid><orcidid>https://orcid.org/0000-0002-5563-8234</orcidid><orcidid>https://orcid.org/0000-0001-6264-5304</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-5701 |
| ispartof | International ophthalmology, 2021-10, Vol.41 (10), p.3371-3379 |
| issn | 0165-5701 1573-2630 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2534610460 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Complications Eye Glaucoma Hypotonia Intraocular pressure Medicine Medicine & Public Health Ophthalmology Original Paper Patients Surgery |
| title | Multicenter case series of standalone XEN implant vs. combination with phacoemulsification in Turkish patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A04%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicenter%20case%20series%20of%20standalone%20XEN%20implant%20vs.%20combination%20with%20phacoemulsification%20in%20Turkish%20patients&rft.jtitle=International%20ophthalmology&rft.au=Eraslan,%20Muhsin&rft.date=2021-10-01&rft.volume=41&rft.issue=10&rft.spage=3371&rft.epage=3379&rft.pages=3371-3379&rft.issn=0165-5701&rft.eissn=1573-2630&rft_id=info:doi/10.1007/s10792-021-01899-7&rft_dat=%3Cproquest_cross%3E2534610460%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2574104791&rft_id=info:pmid/&rfr_iscdi=true |